SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Moulton G. Community Clinical Oncology Program celebrates 20 years of trials and a few tribulations. J Natl Cancer Inst. 2003; 95: 1822-1824.
  • 2
    Frelick RW. The Community Clinical Oncology Program (CCOP) story: review of community oncologists' experiences with clinical research trials in cancer with an emphasis on the CCOP of the National Cancer Institute between 1982 and 1987. J Clin Oncol. 1994; 12: 1718-1723.
  • 3
    Cobau CD. Clinical trials in the community. The community clinical oncology program experience. Cancer. 1994; 74: 2694-2700.
  • 4
    Hunter CP, Bavier AR, Ford LG. Cancer control research for community programs: the National Cancer Institute initiative. Cancer Detect Prev. 1990; 14: 633-637.
  • 5
    Minasian LM, Carpenter WR, Weiner BJ, et al. Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program. Cancer. 2010; 116: 4440-4449.
  • 6
    Mills EJ, Seely D, Rachlis B, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systemic review of patient-reported factors. Lancet Oncol. 2006; 7: 141-148.
  • 7
    Townsley CA, Selby R, Siu LL. Systematic review of barriers to recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005; 23: 3112-3124.
  • 8
    Mouton CP, Harris S, Rovi S, et al. Barriers to black women's participation in cancer clinical trials. J Natl Med Assoc. 1997; 89: 721-727.
  • 9
    Adams-Campbell LL, Ahaghotus C, Gaskins M, et al. Enrollment of African Americans onto clinical treatment trials: study design barriers. J Clin Oncol. 2004; 22: 730-734.
  • 10
    Simon MS, Brown DR, Du W, Lorusso P, Kellogg CM. Accrual to breast cancer clinical trials at a university-affiliated hospital in metropolitan Detroit. Am J Clin Oncol. 1999; 22: 42-46.
  • 11
    Kaluzny A, Brawley O, Garson-Angert D, et al. Assuring access to state-of-the-art care for US minority populations: the first 2 years of the Minority-Based Community Clinical Oncology Program. J Natl Cancer Inst. 1993; 85: 1945-1950.
  • 12
    Cook ED, Arnold KB, Hermos JA, et al. Impact of supplemental site grants to increase African American accrual for the Selenium and Vitamin E Cancer Prevention Trial. Clin Trials. 2010; 7: 90-99.
  • 13
    Caskill-Stevens W, McKinney MM, Whitman CG, Minasian LM. Increasing minority participation in cancer clinical trials: the minority-based community clinical oncology program experience. J Clin Oncol. 2005; 23: 5247-5254.
  • 14
    Wendler D, Kington R, Madans J, et al. Are racial and ethnic minorities less willing to participate in research [serial online]? PLoS Med. 2006; 3: 19.
  • 15
    Vicini F, Shah C, Wallace M, et al. Strategies for reducing cancer incidence and mortality in African American and Arab American and Chaldean communities in the Detroit metropolitan area. Am J Clin Oncol. In press.
  • 16
    Yee KW, Pater JL, Pho L, et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol. 2003; 21: 1618-1623.
  • 17
    Hutchins LF, Unger JM, Crowley JJ, et al. Under representation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341: 2061-2067.
  • 18
    Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002; 20: 2109-2117.
  • 19
    Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer. 2004; 101: 3-27.
  • 20
    Ward E, Jemal A, Cokkinides V, et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004; 54: 78-93.
  • 21
    Institute of Medicine, Board on Health Sciences Policy. The Unequal Burden of Cancer: An Assessment of NIH Research and Programs for Ethnic Minorities and the Medically Underserved. Washington, DC: National Academies Press; 1999.
  • 22
    Pinsky PF, Ford M, Gamito E, et al. Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. J Natl Med Assoc. 2008; 100: 291-298.
  • 23
    Movsas B, Moughan J, Owen J, et al. Who enrolls onto clinical oncology trials? A radiation patterns of care study analysis. Int J Radiat Oncol Biol Phys. 2007; 15; 68: 1145-1150.
  • 24
    Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer. 2008; 112: 228-242.
  • 25
    Joseph G, Dohan D. Recruiting minorities where they receive care: institutional barriers to cancer clinical trials recruitment in a safety-net hospital. Contemp Clin Trials. 2009; 30: 552-559.
  • 26
    Brewster WR, Anton-Culver H, Ziogas A, et al. Recruitment strategies for cervical cancer prevention study. Gynecol Oncol. 2002; 85: 250-254.
  • 27
    Ford ME, Havstad SL, Davis SD. A randomized trial of recruitment methods for older African American men in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Clin Trials. 2004; 1: 343-351.